Travere Therapeutics (TVTX)
(Real Time Quote from BATS)
$7.48 USD
+0.41 (5.80%)
Updated Jun 12, 2024 09:33 AM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
Travere Therapeutics, Inc. [TVTX]
Reports for Purchase
Showing records 121 - 131 ( 131 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Delving More Into DUPLEX - Raising Target to $46 on TVTX
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
With Most Of The Fireworks Already Shot Off, Looking For Quiet 4Q20 Reporting
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Glomerular Disorders 101: A Deep Dive Primer On Glomerular Dysfunction
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking For More Than Love In The Air In February - DUPLEX Data Feb 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A Wrap On DUPLEX Enrollment; On To The Readout For Sparsentan and TVTX
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L